Fig. 3: The D1 dopamine receptor antagonist, SCH-23390, but not the D2 dopamine receptor antagonist haloperidol, rescues autistic-like symptoms. | Nature Communications

Fig. 3: The D1 dopamine receptor antagonist, SCH-23390, but not the D2 dopamine receptor antagonist haloperidol, rescues autistic-like symptoms.

From: Altered heparan sulfate metabolism during development triggers dopamine-dependent autistic-behaviours in models of lysosomal storage disorders

Fig. 3

a The TH inhibitor α-MPT (250 mg/kg) reduced hyperactivity, aʹ stereotyped behaviour and aʺ the percentage of retreats in MPS-IIIA mice. b SCH-23390 (0.03 and 0.06 mg/kg) rescued hyperactivity, bʹ stereotypies and bʺ social impairment. c Haloperidol (0.05 and 0.1 mg/kg) only rescued hyperactivity at the highest dose, while had no effect on the: cʹ stereotypies and cʺ social impairment. Histograms represent mean ± S.E.M. *p < 0.05 vs WT, between groups; #p < 0.05 vs MPS-IIIA veh, within group.

Back to article page